DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: trastuzumab
Biological: aldesleukin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00006228

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Liver Metastases
Stage IV Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: floxuridine
Drug: dexamethasone
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00026234

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: medroxyprogesterone
Drug: ethinyl estradiol
Other: laboratory biomarker analysis
Drug: norgestrel

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00033358

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase 3

Active, not recruiting

Conditions: Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4S Neuroblastoma
Stage 4 Neuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma

Interventions: Drug: Isotretinoin
Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Biological: Dinutuximab
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Biological: Sargramostim

First Posted Date: 2003-01-27

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1449

Registration Number: NCT00026312

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 194 locations

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00006226

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

CC-5013 in Treating Patients With Recurrent Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00036894

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00030095

Locations: 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020410

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

Phase 1

Completed

Conditions: Vulvar Cancer
Head and Neck Cancer
Anal Cancer
Penile Cancer
Cervical Cancer
Esophageal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019110

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 3 locations

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Phase 1

Completed

Conditions: Lymphoma
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019838

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy